| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/17/2003 | US20030072791 Felodipine transdermal device and methods |
| 04/17/2003 | US20030072789 For towelette or wipes useful for feminine cleansing |
| 04/17/2003 | US20030072785 Mixtures for stimulating glucose up-take |
| 04/17/2003 | US20030072783 Administering nitric oxide adduct to a damaged vascular surface, wherein damaged vascular surface is interior surface of a blood vessel in which damage to endothelium or subendothelium, narrowing or stenosis of vessel has occured |
| 04/17/2003 | US20030072777 Combinatorial anti-acne compositions |
| 04/17/2003 | US20030072770 Compositions of plant carbohydrates as dietary supplements |
| 04/17/2003 | US20030072768 Method to enhance an immune response of nucleic acid vaccination |
| 04/17/2003 | US20030072767 Compositions and methods for WT1 specific immunotherapy |
| 04/17/2003 | US20030072763 Absorb in the low- energy, ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum that are used for the phototherapy of tumors and other lesions |
| 04/17/2003 | US20030072762 For enhancing Fc receptor-mediated antigen presentation, vaccines |
| 04/17/2003 | US20030072760 Anti-estrogen and immune modulator combinations for treating breast cancer |
| 04/17/2003 | US20030072759 Administering to a patient afflicted with a gastrointestinal tumor, a murine monoclonal antibody which specifically binds to an epitope of 17-1A antigen, the antibody being administered parenterally in multiple doses |
| 04/17/2003 | US20030072756 Combination therapy using an IL-1 inhibitor and methotrexate |
| 04/17/2003 | US20030072752 Two novel genes from psoriatic epidermis: psoriastatin type i and psoriastatin type ii |
| 04/17/2003 | US20030072748 Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (Kca) |
| 04/17/2003 | US20030072746 Administering glutaminase inhibitor to a subject suffering from chronic pain at a site of inflammation for therapy of chronic pain |
| 04/17/2003 | US20030072745 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/17/2003 | US20030072740 Pulmonary delivery of active agents |
| 04/17/2003 | US20030072738 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
| 04/17/2003 | US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 04/17/2003 | US20030072735 Radiation protecting agent which comprises, as an active ingredient, a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 |
| 04/17/2003 | US20030072734 Sulphonated comb polymers having a selected lithium/sodium ratio and preparations, in particular hair cosmetic preparations, based on such sulphonated comb polymers |
| 04/17/2003 | US20030072732 Comprises association between elastase inhibitor compound of the N-acylaminoamide family and at least one antiinflammatory compound; for improving skin ageing and/or photoageing signs by slowing down connective tissue alterations |
| 04/17/2003 | US20030072726 Phenolic compounds from natural biological materials such as plant material |
| 04/17/2003 | US20030072724 Topical pharmaceutical composition to treat hyperpigmentation of the skin |
| 04/17/2003 | US20030072711 Eye treatment |
| 04/17/2003 | US20030070903 Systems, methods and apparatuses for manufacturing dosage forms |
| 04/17/2003 | US20030070679 Capsules containing inhalable tiotropium |
| 04/17/2003 | EP0912584A3 New bis-platinum complexes with polyamine ligands as antitumor agents |
| 04/17/2003 | DE4345439C2 Malotilate for accelerating wound healing of damaged tissues |
| 04/17/2003 | CA2812761A1 In vitro model for priocidal activity |
| 04/17/2003 | CA2471968A1 Immunostimulatory nucleic acids and use thereof |
| 04/17/2003 | CA2464662A1 Modulation of the expression of genes dependent on stat-1 |
| 04/17/2003 | CA2463563A1 Kinase inhibitor scaffolds and methods for their preparation |
| 04/17/2003 | CA2463507A1 Methods for the synthesis of substituted purines |
| 04/17/2003 | CA2463442A1 Methods for regulating co-stimulatory molecule expression with reactive oxygen |
| 04/17/2003 | CA2463384A1 Hydrating nasal gel and applicator |
| 04/17/2003 | CA2463364A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 04/17/2003 | CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | CA2463198A1 Pyrrolidinone derivatives |
| 04/17/2003 | CA2463170A1 Antiradicals and fat compositions, foods, drinks, drugs or feeds containing the antiradicals |
| 04/17/2003 | CA2463168A1 An antispasmodic agent spaced drug delivery system |
| 04/17/2003 | CA2463133A1 Styryl acrylonitrile compounds and their use to promote myelopoiesis |
| 04/17/2003 | CA2463105A1 Composition and method for treating graft-versus-host disease |
| 04/17/2003 | CA2462950A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| 04/17/2003 | CA2462913A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| 04/17/2003 | CA2462886A1 Flashmelt oral dosage formulation |
| 04/17/2003 | CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 04/17/2003 | CA2462876A1 Compositions for and methods of treating and preventing sirs/sepsis |
| 04/17/2003 | CA2462875A1 Allylamides useful in the treatment of alzheimer's disease |
| 04/17/2003 | CA2462871A1 In vitro model for priocidal activity |
| 04/17/2003 | CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | CA2462861A1 Piperidine compounds as muscarinic antagonists |
| 04/17/2003 | CA2462840A1 Pseudopterosin compounds of symbiodinium spp isolated from pseudopterogorgia elisabethae |
| 04/17/2003 | CA2462806A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide |
| 04/17/2003 | CA2462801A1 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists |
| 04/17/2003 | CA2462791A1 Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof |
| 04/17/2003 | CA2462582A1 Adjuvants for nucleic acid vaccines |
| 04/17/2003 | CA2462579A1 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 04/17/2003 | CA2462301A1 Para-amino benzoic acids as integrin antagonists |
| 04/17/2003 | CA2462291A1 Methods and compositions for treating dermal lesions |
| 04/17/2003 | CA2462272A1 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue |
| 04/17/2003 | CA2462185A1 Methods for modulating activity of the fxr nuclear receptor |
| 04/17/2003 | CA2461961A1 Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders |
| 04/17/2003 | CA2461960A1 Combinatorial anti-acne compositions |
| 04/17/2003 | CA2461369A1 Arylsulphonyl-substituted tetrahydro-and-hexahydro-carbazoles as 5-ht-6 receptor ligands |
| 04/17/2003 | CA2461291A1 Inhibition of exoprotein production using aromatic compositions |
| 04/17/2003 | CA2461092A1 Pharmaceutical composition for the treatment of disorders of non-human mammals |
| 04/17/2003 | CA2461064A1 Inhibition of stat-1 |
| 04/17/2003 | CA2458473A1 Pharmaceutical formulation |
| 04/17/2003 | CA2458456A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
| 04/17/2003 | CA2458453A1 Acylsulfonamides as inhibitors of steroid sulfatase |
| 04/17/2003 | CA2458446A1 Cyanoacetyl compounds |
| 04/17/2003 | CA2458388A1 Novel benzothiazine derivatives, their preparation and use |
| 04/17/2003 | CA2455999A1 Carbonyloxy-cyanomethyl compounds as antiparasitic agents |
| 04/16/2003 | WO2003032915A2 Viral inhibition by n-docosanol |
| 04/16/2003 | EP1302472A1 Molecules capable of binding to telomere and the like and method with the use of the same |
| 04/16/2003 | EP1302470A1 Lipid-rich plaque inhibitors |
| 04/16/2003 | EP1302468A1 Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| 04/16/2003 | EP1302463A1 Medicine comprising dicyanopyridine derivative |
| 04/16/2003 | EP1302462A1 Sulfone derivatives, process for their production and use thereof |
| 04/16/2003 | EP1302461A1 Tnf-alpha production inhibitors |
| 04/16/2003 | EP1302460A1 Indolecarboxylic compounds and their use as pharmaceutical compounds |
| 04/16/2003 | EP1302205A1 Controlled release formulations of macrolide citrate salts |
| 04/16/2003 | EP1302201A1 Pharmaceutical composition improved in peroral absorbability |
| 04/16/2003 | EP1302200A1 Pharmaceutical formulation of a budesonide-containing water-propylene glycol solution and method of preparing it |
| 04/16/2003 | EP1302115A1 Use of cystathionine |
| 04/16/2003 | EP1302114A2 Mixtures for stimulating glucose up-take |
| 04/16/2003 | EP1302113A1 Physiologically functional foods or cosmetics containing sphingoglycolipids and processes for their production |
| 04/16/2003 | EP1301797A2 Antimicrobial agent |
| 04/16/2003 | EP1301616A2 Bicistronic influenza viruses comprising two genes in tandem |
| 04/16/2003 | EP1301602A2 Fh-binding protein of streptococcus pneumoniae |
| 04/16/2003 | EP1301598A2 Cell cycle proteins and mitosis-associated molecules |
| 04/16/2003 | EP1301593A2 ANTISENSE COMPOSITIONS TARGETED TO $g(b) 1? ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE |
| 04/16/2003 | EP1301528A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 04/16/2003 | EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies |
| 04/16/2003 | EP1301523A1 N8 - and c8 -linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotide hybridization |
| 04/16/2003 | EP1301522A1 Novel compounds and methods |
| 04/16/2003 | EP1301519A2 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 04/16/2003 | EP1301518A1 Tricyclic compounds as mrp1-inhibitors |